What is Syndax Pharmaceuticals Inc Quarterly Revenue?

Syndax Pharmaceuticals Inc Quarterly Revenue Syndax Pharma Inc Jun-2026 Quarterly Revenue is $73 Million which is growth of 91.8% YoY.

What is Syndax Pharmaceuticals Inc Quarterly Net Profit?

Syndax Pharmaceuticals Inc Quarterly Net Profit Syndax Pharma Inc Jun-2026 Quarterly Net Profit is $-49 Million which is growth of 31.3% YoY.

What is Syndax Pharmaceuticals Inc Annual Revenue?

Syndax Pharmaceuticals Inc Annual Revenue Syndax Pharma Inc Dec-2025 Annual Revenue is $172 Million which is growth of 627.8% YoY.

What is Syndax Pharmaceuticals Inc Annual Net Profit?

Syndax Pharmaceuticals Inc Annual Net Profit Syndax Pharma Inc Dec-2025 Annual Net Profit is $-285 Million which is growth of 10.5% YoY.

What is Syndax Pharmaceuticals Inc Total Shareholders Fund?

Syndax Pharmaceuticals Inc Total Shareholders Fund Syndax Pharma Inc Dec-2025 Total Shareholders Fund is $65 Million which is growth of -77.6% YoY.

What is Syndax Pharmaceuticals Inc Total Assets?

Syndax Pharmaceuticals Inc Total Assets Syndax Pharma Inc Dec-2025 Total Assets is $530 Million which is growth of -26.9% YoY.

What is Syndax Pharmaceuticals Inc Book Value Per Share?

Syndax Pharmaceuticals Inc Book Value Per Share Syndax Pharma Inc Book Value Per Share is $1 which is growth of -82.8% YoY.

What is Syndax Pharmaceuticals Inc ROE?

Syndax Pharmaceuticals Inc ROE Syndax Pharma Inc ROE is 0% which is growth of 0% YoY.

What is Syndax Pharmaceuticals Inc Cash From Operating Activity?

Syndax Pharmaceuticals Inc Cash From Operating Activity Syndax Pharma Inc Dec-2025 Cash From Operating Activity is $-323 Million which is growth of -17.5% YoY.

What is Syndax Pharmaceuticals Inc Net Cash Flow?

Syndax Pharmaceuticals Inc Net Cash Flow Syndax Pharma Inc Dec-2025 Net Cash Flow is $-19 Million which is growth of 86.4% YoY.

Syndax Pharmaceuticals Inc

XNAS: SNDX

Weak Stock

Download real time

-0.42(-3.01%)

Near 52W Low of $12.99

3.0M

XNAS Volume

XNAS 14 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Syndax Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Forecaster Analyst Estimates for Syndax Pharma Inc share price target, revenues, EPS, net income and more

Syndax Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue Syndax Pharma Inc Jun-2026 Quarterly Revenue is $73 Million which is growth of 91.8% YoY.
POSITIVE
Quarterly Net Profit Syndax Pharma Inc Jun-2026 Quarterly Net Profit is $-49 Million which is growth of 31.3% YoY.

Syndax Pharmaceuticals Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
SR_Q Operating Rev.	72.8	64.9	68.7	45.9	38	20	7.7	12.5	3.5
CostOfRevenue_Q Cost Of Rev.	3.2	2.6	2.7	2.1	1.3	0.9	-	-	-	-	-	-	-
GrossProfit_Q Gross Profit	69.6	62.2	66	43.8	36.7	19.2	-	-	-	-	-	-	-
OEXPNS_Q Operating Exp. ⌄	109.6	96.4	128.6	101.2	106	102.9	103.2	102.1	77.7	79.5	77.9	56.4	49.7
AdminAndSellingExpenses_Q Admin Plus Selling Exp.	41.5	37.6	49.9	44.9	43.8	41	37.7	31.1	29.1	23	22.8	17.3	14.9
ResearchAndDevlopmentExpenses_Q RnD Exp.	68	58.8	78.6	56.3	62.2	61.6	65.5	71	48.7	56.5	55.1	39.1	34.8
OP_Q Operating Profit	-40	-34.2	-62.6	-57.4	-69.4	-83.8	-96.4	-89.6	-74.2	-79.5	-77.9	-56.4	-49.7
NetNonOperIntIncExp_Q Net Non Operations Interest Incuding Expenses ⌄	-8.9	-8.3	-5.3	-3	-1.9	-0.9	2.3	5.4	6.2	7.2	5.5	5.3	5.2
Others_Q Other Interest Earned	3.8	3.6	4.3	5.3	6	7.2	7.1	5.4	6.3	7.3	5.6	5.3	5.2
IntExpNonOperating_Q Interest Exp. Non Operating	12.7	11.9	9.6	8.3	7.9	8.1	4.8	0	0	0.1	0.1	0.1	0
PBT_Q Profit Before Tax	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
TAX_Q Tax	-	-	-	-	-	-	-	-	-	-	-	-	-
NICommonStockholders_Q Net Income Common Stockholders ⌄	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
NP_Q Net Profit	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
NIIncludingNoncontrollingInterests_Q Net Income Including Non controlling Interests	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
DilutedNIAvailtoComStockholders_Q Diluted NI Avail to Com Stockholders Ann.	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
EPS_Q Basic EPS	-0.6	-0.5	-0.8	-0.7	-0.8	-1	-1.1	-1	-0.8	-0.9	-1	-0.7	-0.6
AfterDilutedEPS_Q Diluted EPS After ExtraOrdinary	-0.6	-0.5	-0.8	-0.7	-0.8	-1	-1.1	-1	-0.8	-0.9	-1	-0.7	-0.6
SHARE_Q Number Of Shares End	89	88.3	86.9	86.6	86.3	86.2	86.6	85.4	85.3	85.2	72.5	69.9	69.6
NIContinuingDiscontinuedOper_Q Net Income Continuing Discontinued Operations	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
NormalizedIncome_Q Normalized Income	-35.4	-30.6	-56.8	-48.6	-58.1	-74.5	-81.9	-72.2	-58.2	-63.5	-64.2	-42.8	-36.6
InterestIncome_Q Interest Income	3.8	3.6	4.3	5.3	6	7.2	7.1	5.4	6.3	7.3	5.6	5.3	5.2
INT_Q Interest	12.7	11.9	9.6	8.3	7.9	8.1	4.8	0	0	0.1	0.1	0.1	0
NetInterestIncome_Q Net Interest Income	-8.9	-8.3	-5.3	-3	-1.9	-0.9	2.3	5.4	6.2	7.2	5.5	5.3	5.2
EBIT_Q EBIT	-40.4	-34.4	-62.8	-57.7	-69.9	-84	-96.5	-89.6	-74.3	-79.6	-78	-56.4	-49.8
EBITDA_Q EBITDA	-40.4	-34.4	-62.8	-57.7	-69.9	-84	-96.5	-89.5	-74.3	-79.6	-78	-56.4	-49.8
ReconciledCostOfRevenue_Q Reconciled Cost Of Rev.	3.2	2.6	2.7	2.1	1.3	0.9	-	-	-	-	-	-	-
ReconciledDepreciation_Q Reconciled Depr.	0
ProfitLossFromContinuingOperations_Q Profit From Continuing Operations	-49.4	-42.7	-68	-60.7	-71.9	-84.9	-94.2	-84.1	-68.1	-72.4	-72.5	-51.2	-44.6
NormalizedEBITDA_Q Normalized EBITDA	-36.7	-30.8	-58.4	-52.4	-64	-76.8	-89.4	-84.1	-68	-72.3	-72.4	-51.1	-44.6

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Syndax Pharma Inc competitor comparison and performance snapshot within industry

Syndax Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Syndax Pharma Inc Dec-2025 Annual Revenue is $172 Million which is growth of 627.8% YoY.
POSITIVE
Annual Net Profit Syndax Pharma Inc Dec-2025 Annual Net Profit is $-285 Million which is growth of 10.5% YoY.

Syndax Pharmaceuticals Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
SR_A Total Rev. Ann. ⌄	-	158.3%		172.4	23.7			139.7	1.5	1.5	1.5	2.1	1.2	0.6
TotalOperatingRevenues_A Operating Rev. Ann.	-	158.3%	252.3	172.4	23.7			139.7	1.5	1.5	1.5	2.1	1.2	0.6
CostOfRevenue_A Cost Of Rev. Ann.	-	-	10.6	7	0.8	-	-	-	-	-	-	-	-	-
GrossProfit_A Gross Profit Ann.	-	-	241.6	165.4	22.9	-	-	-	-	-	-	-	-	-
OEXPNS_A Operating Exp. Ann.	42.4%	43.2%	435.8	438.5	362.5	230	151.8	113.5	72.9	59.1	77.4	64.1	45	21.1
OP_A Operating Profit Ann.	-	-	-194.2	-273.1	-339.7	-230	-151.8	26.2	-71.4	-57.5	-75.9	-62	-43.8	-20.5
NetNonOperIntIncExp_A Net Non Operations Interest Incuding Expenses Ann, ⌄	-	-	-25.5	-11.1	21.2	21	2.7	-1.5	-1.5	1.6	1.9	1.4	1	-1.4
Others_A Other Interest Earned Ann.	56.7%	95.2%	16.9	22.7	26.1	21.2	5.9	0.4	0.8	-	-	-	-	0.2
IntExpNonOperating_A Interest Exp. Non Operating Ann.	121.7%	69.7%	42.4	33.8	4.9	0.2	3.1	1.9	2.4	-	-	-	-	1.6
OtherExpenses_A Other Exp. Ann.	-	-		-1.3	-0.3	-0.4	-0.3	0.2	-0.2	-0.1	-0	-0.3	-1.7	-2.2
PBT_A PBT Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
TAX_A Tax Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NICommonStockholders_A Net Income Common Stockholders Ann. ⌄	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-77.1	-56.1	-74	-60.8	-47.1	-21.8
NP_A Net Profit Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
NIIncludingNoncontrollingInterests_A Net Income Including Non controlling Interests Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
DilutedNIAvailtoComStockholders_A Diluted NI Avail to Com Stockholders Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-77.1	-56.1	-74	-60.8	-47.1	-21.8
EPS_A EPS Ann.	-	-		-3.3	-3.7	-3	-2.5	0.5	-1.9	-1.8	-2.9	-2.9	-3.2	-2.3
DilutedEPS_A Diluted EPS Ann.	-	-		-3.3	-3.7	-3	-2.5	0.5	-1.9	-1.8	-2.9	-2.9	-3.2	-2.3
SHARE_Q Number Of Shares End	11.2%	13.5%		86.9	86.6	72.5	63.2	53.2	46.1	31.7	26.8	24	18.2	6.6
TotalExpenses_A Total Exp. Ann.	43.2%	43.6%		445.4	363.4	230	151.8	113.5	72.9	59.1	77.4	64.1	45	21.1
NIContinuingDiscontinuedOper_A Net Income Continuing Discontinued Operations Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
NormalizedIncome_A Normalized Income Ann.	-	-	-171.4	-237.9	-275.7	-178.4	-133.5	34.4	-64.1	-50	-67.8	-55.4	-38.1	-18.1
InterestIncome_A Interest Income Ann.	56.7%	95.2%	16.9	22.7	26.1	21.2	5.9	0.4	0.8	-	-	-	-	0.2
INT_A Interest Ann.	121.7%	69.7%	42.4	33.8	4.9	0.2	3.1	1.9	2.4	-	-	-	-	1.6
EBITDA_A EBITDA Ann.	-	-	-195.3	-274.4	-339.9	-230.3	-152	26.5	-71.6	-57.5	-75.8	-62.2	-45.3	-22.7
ReconciledCostOfRevenue_A Reconciled Cost Of Rev. Ann.	-	-	10.6	7	0.8	-	-	-	-	-	-	-	-	-
ReconciledDepreciation_A Reconciled Depr. Ann.	-	-	0	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-220.8	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
NormalizedEBITDA_A Normalized EBITDA Ann.	-	-	-178.4	-251.6	-313.8	-209.1	-146.2	26.9	-70.7	-57.5	-75.8	-61.9	-42	-20.4

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

627.4%

5Y CAGR

158.3%

7Y CAGR

96.9%

10Y CAGR

76.1%

Total Revenue Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

21%

2Y CAGR

38.1%

3Y CAGR

42.4%

5Y CAGR

43.2%

7Y CAGR

28.1%

10Y CAGR

35.4%

Operating Expenses Annual Cr growth is lower than historical averages.

Syndax Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Total Shareholders Fund Syndax Pharma Inc Dec-2025 Total Shareholders Fund is $65 Million which is growth of -77.6% YoY.
NEGATIVE
Total Assets Syndax Pharma Inc Dec-2025 Total Assets is $530 Million which is growth of -26.9% YoY.

Syndax Pharmaceuticals Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
TA_A Total Assets Ann. ⌄	2.1%	12%	529.7	724.8	612.9	497.2	449.7	300.6	63.5	83.9	137.2	109	89.9
CA_A Total Current Assets Ann.	2.5%	12.1%	528.1	603.1	580.9	489.8	448.4	298.9	62.3	83.4	133.4	108.5	88
CashEquivalentsShortTermInvestments_A Cash Equivalents and Short Term Investments Ann.	-5.1%	7.1%	413.7	582.9	577.6	484.4	439.9	293.1	59.8	80.9	130	105.3	87.3
Receivables_A Change In Account Receivables Ann.	157.9%	223%	70.3	13.9	1.2	4.1	0.4	0.2	0.1	0.3	0.4	0.3	0.3
Inventories_A Inventories Ann.	-	-	32.8	0.4	-	-	-	-	-	-	-	-	-
OtherCurrentAssets_A Other Current Assets Ann.	81.7%	32%	1.2	0.6	0.1	0.2	0.4	0.3	0.8	1.1	1.3	0.5	0.2
TotalNonCurrentAssets_A Total Non Current Assets Ann.	-40.2%	-2.3%	1.6	121.8	32	7.5	1.3	1.8	1.2	0.6	3.7	0.5	1.9
NetPPE_A Net PPE Ann.	10.9%	24.6%	1.5	2	1.5	1.1	1.3	0.5	1	0.4	0.3	0.3	0.1
InvestmentsAndAdvances_A Investments & Advances Ann.	-	-		119.5	29.8	5.5	-	-	-		3.3	-	-
OtherNonCurrentAssets_A Other Non Current Assets Ann.	-51.9%	-40.1%	0.1	0.2	0.7	0.9	-	1.3	0.2	0.2	0.2	0.2	1.8
TotalLiabilitiesNetMinorityInterest_A Total Liabilities Net Minority Interest Ann. ⌄	149.9%	57.2%	465.1	436.7	58.7	29.8	41.3	48.4	31.9	30.9	32.9	24.9	23.2
CL_A Total Current Liabilities Ann.	60.4%	44.7%	120.1	103.6	58.1	29.1	20.7	18.9	18.4	16.1	15.8	10.4	4.9
PayablesAndAccruedExpenses_A Payables & Accrued Exp.s Ann.	56.6%	50.5%	84.8	75.2	45	22.1	14.1	11	13.3	11.7	11.7	7.1	2.6
CurrentDebtCapLeaseObligation_A Current Debt Cap Lease Obligation Ann.	7.7%	-28.1%	0.5	12.6	1.1	0.4	0.4	2.6	0.5	-	-	-	-
CurrentDeferredLiabilities_Q Current Deferred Liabilities	-	-	-	-	-	-		1.5	1.5	1.5	1.6	1.2	1.2
OtherCurrentLiabilities_A Other Current Liabilities Ann.	159.6%	83.8%	10.5	1.3	0.9	0.6	1.9	0.5	0.3	0.1	0.2	0.4	0.3
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann.	689.9%	63.4%	345	333.1	0.6	0.7	20.6	29.6	13.6	14.8	17.1	14.5	18.4
LongTermDebtAndCapitalLeaseObligation_Q LT Debt & Capital Lease Obligation	689.9%	80.7%	345	333.1	0.6	0.7	20.6	17.9	0.4	-	-	-	-
TradeandOtherPayablesNonCurrent_A Trade & Other Payables Non Current Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalDeferredCreditsAndOtherNonCurrentLiabilities_A Total Deferred Credits & Other Non Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	-48.3%	-23.8%	64.6	288.1	554.2	467.5	408.4	252.2	31.6	53.1	104.3	84.1	-259.7
EQCAP_A Equity Share Capital Ann.	-48.3%	-23.8%	64.6	288.1	554.2	467.5	408.4	252.2	31.6	53.1	104.3	84.1	66.7
CapitalStock_A Capital Stock Ann.	-	-	0	0	0	0	0	0					326.4
RetainedEarnings_A Retained Earnings Ann.	-	-	-1,506.6	-1,221.2	-902.4	-693	-543.7	-568.6	-495.5	-439.4	-366.1	-305.3	-259.7
GainsLossesNotAffectingRetainedEarnings_A Gains Losses Not Affecting Retained Earnings Ann.	-	-	0.5	0.2	0.2	-0.8	0			-0	-0.1	0.1	0
TotalCapitalization_A Total Capitalization Ann.	-4.4%	8.6%	408.5	619.7	554.2	467.5	428.3	270	31.6	53.1	104.3	84.1	66.7
TangibleAssets_A Tangible Assets Ann.	-48.3%	-23.8%	64.6	288.1	554.2	467.5	408.4	252.2	31.6	53.1	104.3	84.1	66.7
WC_A Working Capital Ann.	-4%	7.8%	408	499.5	522.8	460.7	427.7	280	44	67.2	117.6	98.1	83.2
InvestedCapital_A Invested Capital Ann.	-4.4%	8.4%	408.5	631.8	554.2	467.5	428.3	272.3	31.6	53.1	104.3	84.1	-259.7
TangibleBookValue_A Tangible Book Value Ann.	-48.3%	-23.8%	64.6	288.1	554.2	467.5	408.4	252.2	31.6	53.1	104.3	84.1	-259.7
Borrowings_A Borrowings Ann.	560.3%	75.9%	345.4	345.7	1.6	1.2	21	20.5	0.9	-	-	-	-
NetDebt_A Net Debt Ann.	-	-	209	189.6	-	-	-	-	-	-	-	-	-
ShareIssued_A Share Issued Ann.	8.7%	12.8%	87.4	85.7	84.8	68.1	55	47.9	27.1	24.8	24.4	18.2	17.4
SHARE_Q Number Of Shares End	11.2%	13.5%	86.9	86.6	72.5	63.2	53.2	46.1	31.7	26.8	24	18.2	6.6

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Total Assets Ann.

1Y CHG

-26.9%

2Y CAGR

-7%

3Y CAGR

2.1%

5Y CAGR

12%

7Y CAGR

30.1%

10Y CAGR

19.4%

Total Assets Annual is falling faster than historical averages.

Total Current Liabilities Ann.

1Y CHG

15.9%

2Y CAGR

43.8%

3Y CAGR

60.4%

5Y CAGR

44.7%

7Y CAGR

33.3%

10Y CAGR

37.7%

Total Current Liabilities Annual Cr growth is lower than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

-77.6%

2Y CAGR

-65.9%

3Y CAGR

-48.3%

5Y CAGR

-23.8%

7Y CAGR

2.8%

Total ShareHolders Funds Annual is falling faster than historical averages.

Syndax Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Book Value Per Share Syndax Pharma Inc Book Value Per Share is $1 which is growth of -82.8% YoY.
NEUTRAL
ROE Syndax Pharma Inc ROE is 0% which is growth of 0% YoY.

Syndax Pharmaceuticals Inc, Ratios, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
ROA_A RoA Ann. %	-	-	-	-47.66%	-37.72%	-31.54%	6.64%	-42.33%	-76.02%	-66.90%	-49.39%	-47.33%	-42.52%
ROE_A ROE Ann. %	-	-	-	-75.69%	-40.98%	-34.10%	7.55%	-54.31%	-132.43%	-94.00%	-64.53%	-	-
ROIC_Q ROIC %	-	-	-	-19.3	-17	-10.4	29.6	-11.2	-36.1	-32.1	-19	-12.2	-
OPMPCT_A OPM Ann. %	-	-	-158.45%	-1,434.43%	-	-	18.77%	-4,708.17%	-3,792.95%	-5,001.71%	-2,938.99%	-3,587.38%	-3,271.61%
NBTO_A Inventory Turnover Ratio Ann.	-	-	-	2.3	-	-	-	-	-	-	-	-	-
ASETTO_A Asset Turnover Ann. %	-	-	-	0	-	-	0.4	0	0	0	0	0	0
WCTO_A Working Capital Turnover Ann.	-	-	0.4	0.1			0.3	0	0	0	0	0	0
QuickRatio_A Quick Ratio Ann.	-	-	-	5.8	10	16.8	21.3	15.5	3.3	5	8.3	10.2	18.1
CRATIO_A Current Ratio Ann.	-	-	-	5.8	10	16.9	21.7	15.8	3.4	5.2	8.5	10.5	18.2
IC_A Interest Coverage Ratio Ann.	-	-	-	-63.7	-1,005.5	-46.6	14.1	-30	-	-	-	-	-14.3
LTDE_A LT Debt To Equity Ann.	-	-	-	1.2			0.1	0.1	0	-	-	-	-

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Syndax Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level

Base Level

Reporting Type

Originally Reported

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity Syndax Pharma Inc Dec-2025 Cash From Operating Activity is $-323 Million which is growth of -17.5% YoY.
POSITIVE
Net Cash Flow Syndax Pharma Inc Dec-2025 Net Cash Flow is $-19 Million which is growth of 86.4% YoY.

Syndax Pharmaceuticals Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Dec '25	Dec '24	Dec '23	Dec '22	Dec '21	Dec '20	Dec '19	Dec '18	Dec '17	Dec '16	Dec '15
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-323	-274.9	-160.6	-133.7	29.1	-71.3	-50.6	-68.5	-47.4	-35.2	-2.4
ProfitLossFromContinuingOperations_A Profit From Continuing Operations Ann.	-	-	-285.4	-318.8	-209.4	-149.3	24.9	-73.2	-56.1	-74	-60.8	-44.5	-24.1
DepreciationAmortizationDepletion_A Depreciation Amortization Depletion Ann.	-	-	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0
DepreciationAndAmortization_A Depreciation And Amortization Ann.	-	-	0	0	0	0	0	0.1	0.1	0.1	0.1	0.1	0
DeferredTax_A Deferred Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
DeferredIncomeTax_A Deferred Income Tax Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
EmployeesStockOptions_A ESOPs Ann.	43.7%	39.2%	47.5	43	31	16	13.3	9.1	6	6.2	5.5	4.7	3.9
OtherNonCashItems_A Other Non Cash Items Ann.	-4.7%	10.2%	1.3	1	0.7	1.5	0.2	0.8	0.4	0	0	0	0.8
ChangeInWorkingCapital_A Change In Working Capital Ann.	-	-	-79.3	13.3	31.9	1.7	-9.6	-7.9	-0.2	-0.3	7.7	2.9	14.6
ChangeInReceivables_A Change In Receivables Ann.	-	-	-79.8	-11.2	-	-3.5	-	-	-	-	-	-	-
ChangeInInventory_A Change In Inventory Ann.	-	-	-32.1	-0.4	-	-	-	-	-	-	-	-	-
ChangePayablesAccruedExpense_A Change Payables Accrued Expense Ann.	79.8%	-	47.1	20.8	20.5	8.1	4.9	-2.1	1.3	0.2	5.1	5.8	-0.9
ChangeInOtherCurrentAssets_A Change In Other Current Assets Ann.	-	-		0.5	-	-	-	-	-	-	-	-	-
ChangeInOtherCurrentLiabilities_A Change In Other Current Liabilities Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
ChangeInOtherWorkingCapital_A Change In Other Working Capital Ann.	-	-	-	12	10.7	-	-13.1	-1.5	-1.5	-1.5	2.9	-1.2	16.7
CFI_A Cash from Investing Act. Ann. ⌄	-	-	290	-219.8	117.6	-186.2	-40.9	-142.5	12.8	51.4	-17	-18.4	-61.7
NetPPEPurchaseAndSale_A Net PPE Purchase & Sale Ann.	-	-	-0.2			0.2	-0.1			-0.2	-0.1	-0.3	-0.1
PurchaseOfPPE_A Purchase Of PPE Ann.	-	-	-0.2	-			-0.1			-0.2	-0.1	-0.3	-0.1
NetBusinessPurchaseAndSale_A Net Business Purchase & Sale Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfBusiness_A Purchase Of Business Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
PurchaseOfInvestment_A Purchase Of Investment Ann.	-	-	-195.8	-557.1	-354.6	-495.4	-294.7	-278.9	-104	-78.8	-152.3	-158.3	-102
SaleOfInvestment_A Sale Of Investment Ann.	16.3%	28.9%	486	337.3	472.2	308.9	254	136.4	116.8	130.4	135.3	140.3	40.5
NetOtherInvestingChanges_A Net Other Investing Changes Ann.	-	-	-	-	-	-	-	-	-	-	0	-0.1	-0.1
CFA_A Cash from Financing Act. Ann. ⌄	-57%	-46.2%	13.7	353.4	264.1	172.3	118.5	304.4	28.6	15.7	75.7	54.2	77.3
NetIssuancePaymentsOfDebt_A Net Issuance Payments Of Debt Ann.	-	-	-			-21		19.7	-	-	-		-9
NetLongTermDebtIssuance_A Net Long Term Debt Issuance Ann.	-	-	-			-21		19.7	-	-	-		-9
NetShortTermDebtIssuance_A Net ST Debt Issuance Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetCommonStockIssuance_A Net Common Stock Issuance Ann.	-	-			258.1	181.8	86.3	277.7	28.2	15.5	75.4	52.2	-
CommonStockIssuance_A Common Stock Issuance Ann.	-	-			258.1	181.8	86.3	277.7	28.2	15.5	75.4	52.2	-
CommonStockPayments_A Common Stock Payments Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
dividend_1Y_actual Dividend 1year	-	-
DividendPerShare_A Dividend Per Share Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
NetOtherFinancingCharges_A Net Other Financing Charges Ann.	-	-	-	343.7	-	-	0.6		-	0	-		-1.3
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	21.9%	3.2%	135	154.3	295.6	74.5	222.1	115.4	24.7	34	35.2	23.8	23.2
NetIncDecInCashAndCashEquivalents_A Net Increase In Cash Plus Cash Eqv.s Ann.	-	-	-19.3	-141.3	221.1	-147.6	106.7	90.6	-9.3	-1.4	11.3	0.7	13.2
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	-11.4%	44.3%	154.3	295.6	74.5	222.1	115.4	24.7	34	35.4	23.8	23.2	10
IncomeTaxPaidSupplementalData_A Income Tax Paid Supplemental Data Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
InterestPaidSupplementalData_A Interest Paid Supplemental Data Ann.	-	-	13.2			-	-	-	-	-	-	-	0.7
CapitalExpenditure_A Capex Ann.	-	-	-0.2	-	-	-	-0.1	-	-	-0.2	-0.1	-0.3	-0.1
IssuanceOfCapitalStock_A Issuance Of Capital Stock Ann.	-	-			258.1	181.8	86.3	277.7	28.2	15.5	75.4	52.2	87.3
IssuanceOfDebt_A Issuance Of Debt Ann.	-	-	-	-	-			19.7	-	-	-		-
RepaymentOfDebt_A Repayment Of Debt Ann.	-	-	-			-21	-	-	-	-	-		-9
RepurchaseOfCapitalStock_A Repurchase Of Capital Stock Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
FreeCashFlow_A Free Cash Flow Ann.	-	-	-323.2	-274.9	-160.6	-133.7	29	-71.3	-50.6	-68.7	-47.5	-35.4	-2.5

*All financials are in USD Million and price data in USD

Add metric to table

Search...

Cash from Investing Act. Ann.

2Y CAGR

57%

7Y CAGR

28%

Cash from Investing Activity Annual growth is higher than historical averages.

Cash from Financing Act. Ann.

1Y CHG

-96.1%

2Y CAGR

-77.2%

3Y CAGR

-57%

5Y CAGR

-46.2%

7Y CAGR

-1.9%

10Y CAGR

-15.9%

Cash from Financing Annual Activity is falling faster than historical averages.

Forecaster
Quarterly
Competitors/Peers
Annual
Balance Sheet
Ratios
Cash Flow

Near 52W Low of $12.99

Syndax Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

Syndax Pharma Inc - Forecaster

Forecaster Analyst Estimates for Syndax Pharma Inc share price target, revenues, EPS, net income and more

Syndax Pharma Inc - Earnings Report - Quarterly Results

Syndax Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Quarterly Revenue Syndax Pharma Inc Jun-2026 Quarterly Revenue is $73 Million which is growth of 91.8% YoY.

Quarterly Net Profit Syndax Pharma Inc Jun-2026 Quarterly Net Profit is $-49 Million which is growth of 31.3% YoY.

Syndax Pharma Inc - Competitors/Peers

Syndax Pharma Inc competitor comparison and performance snapshot within industry

Syndax Pharma Inc - Earnings Report - Annual Results

Syndax Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Annual Revenue Syndax Pharma Inc Dec-2025 Annual Revenue is $172 Million which is growth of 627.8% YoY.

Annual Net Profit Syndax Pharma Inc Dec-2025 Annual Net Profit is $-285 Million which is growth of 10.5% YoY.

Syndax Pharma Inc - Balance Sheet

Syndax Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Total Shareholders Fund Syndax Pharma Inc Dec-2025 Total Shareholders Fund is $65 Million which is growth of -77.6% YoY.

Total Assets Syndax Pharma Inc Dec-2025 Total Assets is $530 Million which is growth of -26.9% YoY.

Syndax Pharma Inc - Ratios

Syndax Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Book Value Per Share Syndax Pharma Inc Book Value Per Share is $1 which is growth of -82.8% YoY.

ROE Syndax Pharma Inc ROE is 0% which is growth of 0% YoY.

Syndax Pharma Inc - Cash Flow

Syndax Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Cash From Operating Activity Syndax Pharma Inc Dec-2025 Cash From Operating Activity is $-323 Million which is growth of -17.5% YoY.

Net Cash Flow Syndax Pharma Inc Dec-2025 Net Cash Flow is $-19 Million which is growth of 86.4% YoY.